Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Commentary

COVID-19 vaccination and critical care capacity: Perilous months ahead

Leslie A. Reperant, Albert D.M.E. Osterhaus

Artemis One Health Research Foundation, Molengraaffsingel 10, 2629JD Delft, The Netherlands
Research Center on Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Bünteweg 2, 30559 Hannover, Germany

Keywords:
SARS-CoV-2
Control
Non-pharmaceutical intervention
Vaccines
Virus variants

1. Commentary

Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of pandemic COVID-19, spread to virtually all countries around the world in the first half of 2020 [1]. It caused resurging waves of infections in the fall and winter of 2020–2021, especially in northern hemisphere countries. In many countries, hospitals experienced unsustainable pressure on their critical care capacity, as had been experienced at the pandemic onset. This has necessitated the reinstatement of national or territorial lockdowns to drastically curb the flow of inpatients. However, lockdowns have a profound negative socio-economic impact, in particular on the disadvantaged [2]. Although lockdowns have a profound negative socio-economic impact, in particular on the disadvantaged [2]. Although lockdowns have a profound negative socio-economic impact, in particular on the disadvantaged [2].

As of the end of 2020 or beginning of 2021 in a number of countries, the risk of renewed widespread lockdowns remains. Using available data on daily COVID-19 incidence and growth rate in eleven European countries that reinstated a national lockdown in fall 2020, we show a high risk of short-term overwhelming of critical care capacity, as levels of population immunity remain below targeted herd immunity. To avoid the repeated widespread implementation and relaxation of lockdowns, we advocate that controlled conditions brought by current national lockdowns should be leveraged to eliminate SARS-CoV-2 circulation in the community.

Early mathematical models rapidly demonstrated the need for swift suppression of viral spread to curtail the burden on hospital care, largely due to precipitously overtaken regular and intensive care services [3–5]. When overwhelmed, healthcare systems face unsurmountable challenges for the provision of standards of care for COVID-19 and non-COVID-19 inpatients alike. Eventually, the unavoidable need for inpatient triage can dramatically increase the mortality burden and overall emerging pandemic impact. Improved standards of care and treatment options for COVID-19 patients have contributed to decreased case fatality rates in hospitals [6]. Likewise, non-pharmaceutical interventions have contributed to reduced transmission [7], as measured by the effective reproduction number ($R_{\text{eff}}$), i.e., the average number of new cases caused by one infected individual. However, the pandemic potential of SARS-CoV-2 has intrinsically not diminished and continues to threaten society, including through the emergence of more transmissible strains, like B.1.1.7 [8] and others, with hospitals in the front line and economies suffering dramatically. Before envisaged COVID-19 vaccination coverage achieves sufficient levels of herd immunity, critical care capacity remains at risk of becoming overwhelmed.

Considering the maximum number of daily cases of COVID-19 infections occurring during the week prior to the reinstatement of a national lockdown, as a proxy to define the incidence threshold to engage into a national lockdown, one can estimate the time needed for critical care capacity to risk becoming overwhelmed.
as a function of a baseline daily incidence, $R_{eff}$ and corresponding doubling time (Appendix). Such approximations are justifiable when population immunity levels remain well below targeted herd immunity, as currently observed in most countries [9,10]. While the time to the incidence threshold tends to infinity when $R_{eff} = 1.0$, it rapidly decreases with small $R_{eff}$ increments and reaches zero when the baseline incidence equals the incidence threshold (Fig. 1a). On average, the time to the incidence threshold reached 6 months with $R_{eff}$ values of 1.10 (1.07 – 1.13) and 3 months with $R_{eff}$ values of 1.22 (1.15 – 1.28) for the eleven European countries studied (Fig. 1b).

In those European countries that had lifted their first lockdown in May, $R_{eff}$ averaged 1.1 (1.05 – 1.12) from May to the end of October (Fig. A1). At $R_{eff} = 1.1$, it would take an average of 6.4 (5.2 – 7.7) months to reach the incidence thresholds from average daily incidence observed in May (Table 1). In most European countries that reimposed a lockdown in fall 2020, $R_{eff}$ remained above 1.0 since July with an average of 1.2 (1.17 – 1.23) until the end of October. At $R_{eff} = 1.2$, it would take an average of 3.1 (2.8 – 3.5) months for these countries to reach the incidence thresholds from average daily incidence observed in July (Fig. 1c and Table 1). Both estimates fit well with the actual timing of the reinstatement of national lockdowns in the respective countries, end of October or early November 2020.

The proposed calculations have the advantage to estimate the time to risking overwhelming critical care capacity based on $R_{eff}$, independently of the intrinsic transmissibility of circulating viral strains. Time-varying $R_{eff}$ estimated over the course of an epidemic accounts for the impact of public health control measures, the build-up of immunity in the population, or both. Given $k$ the proportion of immune individuals and $g$ the relative reduction in transmission rates due to non-pharmaceutical interventions, $R_{eff}$ can be calculated as $R_{eff} = (1 – k)(1 – g)R_0$ [10]. The resulting relationship between $k$ and $g$ to maintain $R_{eff}$ at particular values is shown in Fig. 1d.

This has important implications. The time estimates to reach the incidence threshold apply similarly to levels of population immunity conferred by previous infection or by vaccination, in the absence of control measures, when these remain below targeted herd immunity. Assuming levels of immunity to SARS-CoV-2 from previous infection and vaccination at 30% in the population, $R_{eff}$ would be reduced to 1.75 (based on a conservative $R_0$ of 2.5), risking overwhelming critical care capacity typically in less than one month, in the absence of other control measures. With 30% of the

![Fig. 1.](image-url) Relationship between the time to reach the incidence threshold ($T$) and the effective reproduction number ($R_{eff}$) for 11 European countries reimposing a national lockdown (Austria, Belgium, Czech Republic, Germany, France, United Kingdom, Greece, Ireland, Lithuania, The Netherlands, Poland). (a) Scatterplot of calculated values of daily $T$ as a function of daily $R_{eff}$ over the period 1st March 2020 to 31st October 2020. (b) Average daily $R_{eff}$ (and standard deviation) of the 11 European countries for monthly bins of daily $T$ values. (c) Average $T$ (and standard deviation) from baseline incidence occurring in July 2020 in the absence of vaccination (black circles) and in the presence of targeted vaccination of priority groups (grey diamonds), from baseline incidence occurring in December 2020 (dark grey squares) and from baseline incidence projected to occur upon lifting lockdowns (white triangles; see Appendix) at $R_{eff}$ values of 1.1, 1.2, 1.3, 1.4, 1.5, 2.0, and 2.5. (d) Relationship between the proportion of immune individuals in the population and the relative reduction in transmission rates due to non-pharmaceutical interventions to maintain $R_{eff}$ at 1.0 (plain line), 1.1 (dashed line) and 1.2 (dotted line). Calculations are based on a conservative $R_0$ of 2.5.
It is important to note that the time to reach the incidence threshold strongly depends on the baseline incidence. In July 2020, most European countries had relatively low daily incidence of COVID-19. Higher baseline incidence may occur upon lifting ongoing lockdowns (Appendix). This would result in shorter times to reach the incidence threshold at corresponding $R_{\text{eff}}$ values.

The implementation of safe and effective vaccination programs is fraught with uncertainty and challenges, especially amidst the current climate of public hesitancy, misinformation and distrust towards vaccines [11]. Although analyses of recently developed COVID-19 vaccines suggest overall high efficacy, for example shortly after booster vaccinations [12,13], the level of efficacy and duration of protection in different age and risk groups and against transmission, including upon infection with newly emerging strains, remain to be determined. Duration of protection may be uncertain for months or years [11]. In addition, extensive research will be needed to address the differential risk factors contributing to infection, morbidity and mortality, the infectious role of younger age-groups and of individuals with asymptomatic or mild infection, the impact of ‘super-spreaders’ and individuals with prior exposure to the virus on the spread of SARS-CoV-2 and its emerging variants, as well as the effect of vaccination on these issues. In parallel, improved surveillance at the human-animal interface will be key to inform about the risk posed by putative animal reservoirs of SARS-CoV-2, such as wildlife and farmed mink. Vaccination programs with currently licensed COVID-19 vaccines further face both logistics and strategic challenges to optimize their impact on controlling the pandemic, requiring complex calculations and well-defined sets of assumptions [11]. By the end of February 2021, COVID-19 vaccination coverage had attained levels below 20% in most countries and below 10% in many countries, including across Europe, and therefore may yet only demonstrate a modest impact on virus circulation.

### Table 1: Time to incidence threshold (in months) under variable conditions.

| $R_{\text{eff}}$ | From first case of COVID-19 | From average baseline incidence in May | From average baseline incidence in July Without vaccination | With targeted vaccination of priority groups | From baseline incidence in December | From projected baseline incidence upon lifting lockdowns$^*$ |
|------------------|-----------------------------|---------------------------------------|-----------------------------------------------------------|------------------------------------------|-----------------------------------|----------------------------------------------------------|
|                  | Ave  | Std  | Ave  | Std  | Ave  | Std  | Ave  | Std  | Ave  | Std  | Ave  | Std  | Ave  | Std  |
| 1.01             | 157.3 | 21.8 | 64.6 | 12.5 | 63.1 | 7.1  | 75.2 | 7.1  | 9.3  | 14.0 | 39.4 | 14.0 |
| 1.05             | 31.4  | 4.4  | 12.9 | 2.5  | 12.6 | 1.4  | 15.0 | 1.4  | 1.8  | 2.8  | 7.8  | 2.8  |
| 1.1              | 15.6  | 2.2  | 6.4  | 1.3  | 6.2  | 0.7  | 7.5  | 0.7  | 0.8  | 1.4  | 3.9  | 1.4  |
| 1.05             | 7.8   | 1.1  | 3.2  | 0.6  | 3.1  | 0.4  | 3.7  | 0.4  | 0.4  | 0.7  | 1.9  | 0.7  |
| 1.1              | 3.1   | 0.7  | 2.1  | 0.4  | 2.0  | 0.2  | 2.4  | 0.2  | 0.2  | 0.5  | 1.2  | 0.5  |
| 1.4              | 3.8   | 0.5  | 1.6  | 0.3  | 1.5  | 0.2  | 1.8  | 0.2  | 0.1  | 0.4  | 0.9  | 0.4  |
| 1.5              | 3.1   | 0.4  | 1.2  | 0.3  | 1.2  | 0.1  | 1.4  | 0.1  | 0.1  | 0.3  | 0.7  | 0.3  |
| 2.0              | 1.5   | 0.2  | 0.6  | 0.1  | 0.6  | 0.1  | 0.7  | 0.1  | 0.0  | 0.1  | 0.3  | 0.1  |
| 2.5              | 1.0   | 0.1  | 0.4  | 0.1  | 0.4  | 0.05 | 0.4  | 0.05 | 0.0  | 0.1  | 0.2  | 0.1  |

Ave = average; Std = standard deviation.

$^*$See Appendix for details on the calculations.

### Figure 1c (and Table 1).

The implementation of safe and effective vaccination programs would need to reduce transmission rates by 31% to maintain $R_{\text{eff}}$ at 1.2 and by 43% to maintain $R_{\text{eff}}$ at 1.0 (Fig. 1d). This would correspond to changes in $R_{\text{eff}}$ of −0.75 to −0.55. The thorough analyses of Haug et al. [7] have shown that i) no single control measures have such an impact on $R_{\text{eff}}$ and ii) that the most effective combined measures to significantly reduce $R_{\text{eff}}$ can be particularly intrusive in restricting physical contact and movement. In other words, as population immunity levels remain low, substantial limitations on gatherings and mobility will need to be maintained upon SARS-CoV-2 circulation to prevent overwhelming of critical care capacity.

As immunity builds up in the population, the main assumption supporting the proposed approximations eventually will be falsified. However, as seen above, reaching the incidence threshold risking the overwhelming of critical care capacity inevitably calls for drastic restrictive measures, such as lockdowns, to curb the disease spread, resulting in cyclic slow-down of active virus circulation as widespread lockdowns are implemented and relaxed. This results in a stepwise population immunity build-up during each cycle. Using the same approximations as previously, the cumulative number of infections at the time of reaching the incidence threshold can be estimated based on $R_{\text{eff}}$ (Appendix; Fig. A2). The higher $R_{\text{eff}}$, the shorter the time to the incidence threshold and the lower the cumulative number of infections upon reinstatement of drastic control measures. This results in a particularly slow build-up of immunity in the population, e.g. of an average of about 5% when $R_{\text{eff}} = 1.1$, and likely contributed to the seemingly low COVID-19 seroprevalence in most countries after the first wave of the pandemic [9,10]. Consequently, conditions for the proposed approximations are likely to be maintained over several successive lockdown implementation and relaxation cycles and thus several months, in the absence of vaccination and continued circulation of SARS-CoV-2.

Table 1 above illustrates in Fig. 1c (and Table 1).

#### Table 1: Time to incidence threshold (in months) under variable conditions.

| $R_{\text{eff}}$ | From first case of COVID-19 | From average baseline incidence in May | From average baseline incidence in July Without vaccination | With targeted vaccination of priority groups | From baseline incidence in December | From projected baseline incidence upon lifting lockdowns$^*$ |
|------------------|-----------------------------|---------------------------------------|-----------------------------------------------------------|------------------------------------------|-----------------------------------|----------------------------------------------------------|
|                  | Ave  | Std  | Ave  | Std  | Ave  | Std  | Ave  | Std  | Ave  | Std  | Ave  | Std  | Ave  | Std  |
| 1.01             | 157.3 | 21.8 | 64.6 | 12.5 | 63.1 | 7.1  | 75.2 | 7.1  | 9.3  | 14.0 | 39.4 | 14.0 |
| 1.05             | 31.4  | 4.4  | 12.9 | 2.5  | 12.6 | 1.4  | 15.0 | 1.4  | 1.8  | 2.8  | 7.8  | 2.8  |
| 1.1              | 15.6  | 2.2  | 6.4  | 1.3  | 6.2  | 0.7  | 7.5  | 0.7  | 0.8  | 1.4  | 3.9  | 1.4  |
| 1.05             | 7.8   | 1.1  | 3.2  | 0.6  | 3.1  | 0.4  | 3.7  | 0.4  | 0.4  | 0.7  | 1.9  | 0.7  |
| 1.1              | 3.1   | 0.7  | 2.1  | 0.4  | 2.0  | 0.2  | 2.4  | 0.2  | 0.2  | 0.5  | 1.2  | 0.5  |
| 1.4              | 3.8   | 0.5  | 1.6  | 0.3  | 1.5  | 0.2  | 1.8  | 0.2  | 0.1  | 0.4  | 0.9  | 0.4  |
| 1.5              | 3.1   | 0.4  | 1.2  | 0.3  | 1.2  | 0.1  | 1.4  | 0.1  | 0.1  | 0.3  | 0.7  | 0.3  |
| 2.0              | 1.5   | 0.2  | 0.6  | 0.1  | 0.6  | 0.1  | 0.7  | 0.1  | 0.0  | 0.1  | 0.3  | 0.1  |
| 2.5              | 1.0   | 0.1  | 0.4  | 0.1  | 0.4  | 0.05 | 0.4  | 0.05 | 0.0  | 0.1  | 0.2  | 0.1  |

Ave = average; Std = standard deviation.

$^*$See Appendix for details on the calculations.
tion against COVID-19 therefore may not prevent the overwhel-
mring of critical care capacity in the coming months, if $R_{\text{eff}}$ remains close to, yet above, the critical value of 1.0 upon lifting restriction measures.

The proposed calculations are based on simplified assumptions of the transmission dynamics of SARS-CoV-2 and have limitations. As seen above, the approximations can only be justified when levels of immunity in the population remain below targeted herd immunity and thus cannot apply when the build-up of immunity through infection or vaccination approaches or reaches such levels. We nonetheless argue that the proposed calculations serve their purpose to demonstrate the risk of overwhelming critical care capacity in the coming months while vaccination programs become initiated, in view of enduring uncertainties on achievable vaccination coverage and timelines. The calculations are dependent on relatively uncertain measures of daily incidence and time-varying effective reproduction numbers, based on incomplete data of varying accuracy. However, sensitivity analyses demonstrate the robustness of the calculations to variations in the estimated parameters (Table A1 and Fig. A4). The proposed calculations further assume that critical care capacity and the proportion of hospitalized patients needing intensive care remain unchanged. Critical care capacity has increased in most countries since the start of the pandemic and improved treatment options may reduce the proportion of inpatients requiring intensive care in the near future. The impact of such changes is nevertheless expected to be limited due to the different orders of magnitude between these changes and the flow of inpatients during current and potential upcoming waves.

National lockdowns are the only option left to prevent overwhel-
mring healthcare systems in countries where the spread of COVID-19 tends to fall out of control. The WHO urges governments to avoid the use of national or widespread lockdowns as the main control strategy against COVID-19, due to the disruptive socio-economic consequences of their repeated implementation and relaxation [2]. Current mitigation strategies—aimed at controlling but not eliminating SARS-CoV-2 circulation—as adopted by most northern hemisphere countries have shown limitations in maintaining $R_{\text{eff}}$ close to 1.0. Based on the work of Haug et al. [7], similarly restrictive measures on contact and mobility as applied during lockdowns may be necessary to maintain SARS-CoV-2 $R_{\text{eff}}$ at sufficiently low levels to prevent repeated short-term overwhelming of critical care capacity. Continuing rigorous non-pharmaceutical interventions will be necessary before vaccination programs for the population at large achieve sufficient levels of herd immunity.

Enforcing restrictive measures over a long period tend to lead to public fatigue and waning public compliance, further complicating effective control of virus circulation levels. Mitigation strategies thus will likely be ineffective as well as unsustainable and socio-economically costly to prevent the repeated overwhelming of critical care capacity in the months to come. This calls for the implementation of control measures aiming at bringing and maintaining $R_{\text{eff}}$ below 1.0 towards the elimination of SARS-CoV-2 community transmission, followed by prevention of COVID-19 importation and prompt stamping out of emerging clusters of infection. Such an approach has been applied successfully in coun-

tries of the eastern and south-eastern hemisphere. These countries offer relevant blueprints for the implementation of this strategy in the northern hemisphere, towards a collaborative and coordinated approach to tackle this unprecedented crisis (Appendix). Priority vaccination of frontline workers and eventually vaccination of the population at large will further strengthen the countries’ purposeful response towards maintaining zero COVID-19 community transmission.

Acknowledgement

We thank the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 398066876/GRK 2485/1, VIPER for funding part of the study.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2021.03.035.

References

[1] World Health Organization. Coronavirus disease (COVID-2019) situation reports. World Health Organisation (2020). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
[2] World Health Organization. Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. (2020). Available at: https://www.who.int/news-room/q-a-detail/herd-immunity-lockdowns-and-covid-19.
[3] Ferguson NM et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial.Ac.Uk 2020. https://doi.org/10.25561/77482.
[4] Kiesler SM, Tedijanto C, Goldstein E, Grad YH, Lipstich M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science (80-. ) 2020;368:860–8.
[5] Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 2020;395:931–4.
[6] Ledford H. Why do COVID death rates seem to be falling?. Nature 2020;587:190–2.
[7] Haug N et al. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav 2020. https://doi.org/10.1038/s41562-020-01009-9.
[8] Volz E et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medRxiv 2021. https://doi.org/10.1101/2020.12.30.20249034.
[9] Rostami A et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect 2020. https://doi.org/10.1016/j.cmi.2020.10.020.
[10] Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we?. Nat Rev Immunol 2020;20:583–4.
[11] Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet 2020. https://doi.org/10.1016/S0140-6736(20)32118-2.
[12] Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ 2020;m4471. https://doi.org/10.1136/bmj.m4471.
[13] Polack FP et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020. https://doi.org/10.1056/NEJMea2034777.